Nail disorders in older people, and aspects of their pharmaceutical treatment by Murdan, S
Table 1a: Cure rates of the most recently approved and most commonly used topical anti-
onychomycotic medicines.  
 Complete cure rate (%) at week 48 following once daily* application  
Topical medicine Trial 1 Trial 2 
 Active Vehicle only Active Vehicle only 
Kerydin* 6.5 0.5 9.1 1.5 
Jublia* 17.8 3.3 15.2 5.5 
Penlac* 5.5 0.9 8.5 0 
Onytec* 5.7 0   
Loceryl Once or twice weekly applications, 13-52% complete cure rates   
 
 
 
Table 1b:  Composition of the medicines in Table 1a 
Product name Active substance* and excipients 
Kerydin Tavaborole* (5%), alcohol, edetate calcium disodium and 
propylene glycol  
Jublia Efinaconazole* (10%), alcohol, anhydrous citric acid, butylated 
hydroxytoluene, C12-15 alkyl lactate, cyclomethicone, diisopropyl 
adipate, disodium edetate, and purified water 
Penlac Ciclopirox* (8%), ethyl acetate, isopropyl alcohol and butyl 
monoester of poly[methylvinyl ether/maleic acid]  
Onytec Ciclopirox* (8%), ethyl acetate, ethanol (96%), cetostearyl alcohol, 
hydroxypropyl-chitosan and purified water  
Loceryl Amorolfine*, ammonio methacrylate copolymer A, triacetin, butyl 
acetate, ethyl acetate, ethanol 
 
 
 
